GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (FRA:ILA) » Definitions » Short Interest

Imugene (FRA:ILA) Short Interest


View and export this data going back to 2024. Start your Free Trial

What is Imugene Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Imugene's Short Interest

For the Biotechnology subindustry, Imugene's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imugene's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imugene's Short Interest distribution charts can be found below:

* The bar in red indicates where Imugene's Short Interest falls into.


;
;

Imugene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (FRA:ILA) » Definitions » Short Interest
Comparable Companies
ASX:DXB ASX:RAC ASX:PAR ASX:OCC ASX:ACW ASX:AGN ASX:ALA ASX:LTP ASX:IMM ASX:EZZ VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
IUGNF:USA IMU:Australia
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Website
https://www.imugene.com
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

Imugene Headlines

No Headlines